ImmunoVaccine Technologies (IVT) Inc, had signed licensing agreements with Pfizer Animal Health to apply IVT's novel VacciMax vaccine platform to the potential development of future, particular livestock vaccines.

Although terms of the agreements were not disclosed, IVT will receive upfront signing fees, milestone and royalty payments.

"We are excited that Pfizer plans to commercialise our technology," said Dr. Randal Chase, president and CEO, ImmunoVaccine Technologies. "We look forward to further discussions with Pfizer to integrate the VacciMax platform into more applications in the fields of animal health care."

The VacciMax vaccine-enhancement platform is comprised of a mixture of liposomes and adjuvants. The VacciMax platform significantly enhances antibody production. IVT has demonstrated that the VacciMax platform not only improves humoral response, but also cell-mediated response (cytotoxic CTL). This is a novel technology that could aid the development of new vaccines in human and animal health applications, with potential for both therapeutic cancer applications and preventative infectious disease vaccines. In pre-clinical animal models, IVT's research shows that the VacciMax platform has the ability to greatly enhance the effectiveness of antigens and could provide a new way to treat a wide range of diseases.

Pfizer, Inc., the world's largest research-based biomedical and pharmaceutical company, also is a world leader in discovering and developing innovative animal vaccines and prescription medicines.

ImmunoVaccine Technologies Inc. (IVT) is a clinical stage vaccine development company focused on commercialisation of its novel vaccine candidates.